- Home
- BIAF vs NERV Comparison
BIAF vs NERV Comparison
Compare BIAF & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- NERV
- Stock Information
- Founded
- BIAF 2014
- NERV 2007
- Country
- BIAF United States
- NERV United States
- Employees
- BIAF N/A
- NERV N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- NERV Health Care
- Exchange
- BIAF Nasdaq
- NERV Nasdaq
- Market Cap
- BIAF 13.0M
- NERV 14.6M
- IPO Year
- BIAF 2022
- NERV 2014
- Fundamental
- Price
- BIAF $2.49
- NERV $4.60
- Analyst Decision
- BIAF Hold
- NERV Hold
- Analyst Count
- BIAF 1
- NERV 1
- Target Price
- BIAF N/A
- NERV $5.00
- AVG Volume (30 Days)
- BIAF 3.3M
- NERV 9.3M
- Earning Date
- BIAF 11-13-2025
- NERV 11-05-2025
- Dividend Yield
- BIAF N/A
- NERV N/A
- EPS Growth
- BIAF N/A
- NERV N/A
- EPS
- BIAF N/A
- NERV 1.48
- Revenue
- BIAF $7,681,059.00
- NERV N/A
- Revenue This Year
- BIAF N/A
- NERV N/A
- Revenue Next Year
- BIAF $20.04
- NERV N/A
- P/E Ratio
- BIAF N/A
- NERV $3.06
- Revenue Growth
- BIAF 4.99
- NERV N/A
- 52 Week Low
- BIAF $2.34
- NERV $1.15
- 52 Week High
- BIAF $46.53
- NERV $12.46
- Technical
- Relative Strength Index (RSI)
- BIAF 46.54
- NERV 62.59
- Support Level
- BIAF $2.43
- NERV $4.27
- Resistance Level
- BIAF $3.50
- NERV $12.46
- Average True Range (ATR)
- BIAF 0.29
- NERV 0.86
- MACD
- BIAF -0.09
- NERV 0.19
- Stochastic Oscillator
- BIAF 5.69
- NERV 23.11
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.